174 related articles for article (PubMed ID: 19995790)
1. Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.
Gremer L; De Luca A; Merbitz-Zahradnik T; Dallapiccola B; Morlot S; Tartaglia M; Kutsche K; Ahmadian MR; Rosenberger G
Hum Mol Genet; 2010 Mar; 19(5):790-802. PubMed ID: 19995790
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.
Lorenz S; Lissewski C; Simsek-Kiper PO; Alanay Y; Boduroglu K; Zenker M; Rosenberger G
Hum Mol Genet; 2013 Apr; 22(8):1643-53. PubMed ID: 23335589
[TBL] [Abstract][Full Text] [Related]
3. Attenuated phenotype of Costello syndrome and early death in a patient with an HRAS mutation (c.179G>T; p.Gly60Val) affecting signalling dynamics.
Gripp KW; Kolbe V; Brandenstein LI; Rosenberger G
Clin Genet; 2017 Sep; 92(3):332-337. PubMed ID: 28139825
[TBL] [Abstract][Full Text] [Related]
4. The novel duplication HRAS c.186_206dup p.(Glu62_Arg68dup): clinical and functional aspects.
Gripp KW; Baker L; Robbins KM; Stabley DL; Bellus GA; Kolbe V; Nauth T; Rosenberger G
Eur J Hum Genet; 2020 Nov; 28(11):1548-1554. PubMed ID: 32499600
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.
Rosenberger G; Meien S; Kutsche K
Hum Mutat; 2009 Mar; 30(3):352-62. PubMed ID: 19035362
[TBL] [Abstract][Full Text] [Related]
6. An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.
Gripp KW; Sol-Church K; Smpokou P; Graham GE; Stevenson DA; Hanson H; Viskochil DH; Baker LC; Russo B; Gardner N; Stabley DL; Kolbe V; Rosenberger G
Am J Med Genet A; 2015 Sep; 167A(9):2085-97. PubMed ID: 25914166
[TBL] [Abstract][Full Text] [Related]
7. A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development.
Gripp KW; Bifeld E; Stabley DL; Hopkins E; Meien S; Vinette K; Sol-Church K; Rosenberger G
Am J Med Genet A; 2012 Sep; 158A(9):2106-18. PubMed ID: 22821884
[TBL] [Abstract][Full Text] [Related]
8. Behavioral phenotype in Costello syndrome with atypical mutation: a case report.
Alfieri P; Caciolo C; Piccini G; D'Elia L; Valeri G; Menghini D; Tartaglia M; Digilio MC; Dallapiccola B; Vicari S
Am J Med Genet B Neuropsychiatr Genet; 2015 Jan; 168B(1):66-71. PubMed ID: 25367099
[TBL] [Abstract][Full Text] [Related]
9. HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.
Niihori T; Aoki Y; Okamoto N; Kurosawa K; Ohashi H; Mizuno S; Kawame H; Inazawa J; Ohura T; Arai H; Nabatame S; Kikuchi K; Kuroki Y; Miura M; Tanaka T; Ohtake A; Omori I; Ihara K; Mabe H; Watanabe K; Niijima S; Okano E; Numabe H; Matsubara Y
J Hum Genet; 2011 Oct; 56(10):707-15. PubMed ID: 21850009
[TBL] [Abstract][Full Text] [Related]
10. Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome.
Wey M; Lee J; Jeong SS; Kim J; Heo J
Biochemistry; 2013 Nov; 52(47):8465-79. PubMed ID: 24224811
[TBL] [Abstract][Full Text] [Related]
11. Duplications in the G3 domain or switch II region in HRAS identified in patients with Costello syndrome.
Nagai K; Niihori T; Okamoto N; Kondo A; Suga K; Ohhira T; Hayabuchi Y; Homma Y; Nakagawa R; Ifuku T; Abe T; Mizuguchi T; Matsumoto N; Aoki Y
Hum Mutat; 2022 Jan; 43(1):3-15. PubMed ID: 34618388
[TBL] [Abstract][Full Text] [Related]
12. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.
Gripp KW; Lin AE
Genet Med; 2012 Mar; 14(3):285-92. PubMed ID: 22261753
[TBL] [Abstract][Full Text] [Related]
13. Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation.
Goodwin AF; Tidyman WE; Jheon AH; Sharir A; Zheng X; Charles C; Fagin JA; McMahon M; Diekwisch TG; Ganss B; Rauen KA; Klein OD
Hum Mol Genet; 2014 Feb; 23(3):682-92. PubMed ID: 24057668
[TBL] [Abstract][Full Text] [Related]
14. Aberrant HRAS transcript processing underlies a distinctive phenotype within the RASopathy clinical spectrum.
Pantaleoni F; Lev D; Cirstea IC; Motta M; Lepri FR; Bottero L; Cecchetti S; Linger I; Paolacci S; Flex E; Novelli A; Carè A; Ahmadian MR; Stellacci E; Tartaglia M
Hum Mutat; 2017 Jul; 38(7):798-804. PubMed ID: 28390077
[TBL] [Abstract][Full Text] [Related]
15. C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.
Klüppel M; Samavarchi-Tehrani P; Liu K; Wrana JL; Hinek A
Eur J Hum Genet; 2012 Aug; 20(8):870-7. PubMed ID: 22317973
[TBL] [Abstract][Full Text] [Related]
16. MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model.
Tidyman WE; Goodwin AF; Maeda Y; Klein OD; Rauen KA
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 34553752
[TBL] [Abstract][Full Text] [Related]
17. The rare Costello variant HRAS c.173C>T (p.T58I) with severe neonatal hypertrophic cardiomyopathy.
Hiippala A; Vasilescu C; Tallila J; Alastalo TP; Paetau A; Tyni T; Suomalainen A; Euro L; Ojala T
Am J Med Genet A; 2016 Jun; 170(6):1433-8. PubMed ID: 26888048
[TBL] [Abstract][Full Text] [Related]
18. A novel HRAS c.466C>T p.(Phe156Leu) variant in two patients with attenuated features of Costello syndrome.
Lindsey-Temple S; Edwards M; Rickassel V; Nauth T; Rosenberger G
Eur J Hum Genet; 2022 Sep; 30(9):1088-1093. PubMed ID: 35764878
[TBL] [Abstract][Full Text] [Related]
19. Recurrent duplication mutation in HRAS causing mild Costello syndrome in a Chinese patient.
Xu F; Wang HJ; Lin ZM; Yu B
Clin Exp Dermatol; 2015 Jun; 40(4):404-7. PubMed ID: 25677562
[TBL] [Abstract][Full Text] [Related]
20. The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer.
Hartung AM; Swensen J; Uriz IE; Lapin M; Kristjansdottir K; Petersen US; Bang JM; Guerra B; Andersen HS; Dobrowolski SF; Carey JC; Yu P; Vaughn C; Calhoun A; Larsen MR; Dyrskjøt L; Stevenson DA; Andresen BS
PLoS Genet; 2016 May; 12(5):e1006039. PubMed ID: 27195699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
